The Annals Visit the PharmaCE website!
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 27, No. 2, pp. 182-185.
© 1993 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bressler, L.
Right arrow Articles by Warren, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bressler, L.
Right arrow Articles by Warren, R.

Research Articles

Use of clonidine to treat hot flashes secondary to leuprolide or goserelin

LR Bressler, CM Murphy, DH Shevrin, and RF Warren

OBJECTIVE: To determine the effects of clonidine, a centrally acting adrenergic agonist, in abating symptoms of hot flashes in men receiving either leuprolide or goserelin for prostate cancer. DESIGN: Patients were administered transdermal or oral clonidine 0.1-0.2 mg/d. Dosages were increased in increments of 0.1-0.3 mg/d every two to four weeks if symptoms persisted or until adverse effects developed. SETTING: Medical oncology clinic at the University of Illinois and the hypertension clinic at the Veterans Affairs West Side Medical Center. PARTICIPANTS: Consenting male patients were eligible for the study if they were receiving leuprolide or goserelin for prostate cancer and were experiencing hot flashes. Exclusion criteria included diastolic blood pressure of 75 mm Hg or below or a history of adverse reactions to clonidine. MAIN OUTCOME MEASURES: Effectiveness of clonidine was determined by questioning patients about frequency, severity, and duration of hot flashes at baseline and at two- to four-week intervals. RESULTS: All four patients receiving clonidine experienced a partial response within two weeks of starting treatment. No dose-dependent response was observed. Adverse effects were noted in one patient but did not result in discontinuation. CONCLUSIONS: Our results document the first report of the use of clonidine to treat hot flashes secondary to leuprolide or goserelin therapy. Symptomatic improvement was noted in all four patients. Further evaluation of clonidine as well as other centrally acting adrenergic agonists is needed.


This article has been cited by other articles:


Home page
 American Journal of Men's HealthHome page
C. A. Engstrom
Hot Flashes in Prostate Cancer: State of the Science
American Journal of Men's Health, June 1, 2008; 2(2): 122 - 132.
[Abstract] [PDF]

Home page
 American Journal of Men's HealthHome page
C. A. Engstrom and C. E. Kasper
Physiology and Endocrinology of Hot Flashes in Prostate Cancer
American Journal of Men's Health, March 1, 2007; 1(1): 8 - 17.
[Abstract] [PDF]

Home page
 JCOHome page
V. Stearns and D. F. Hayes
Cooling Off Hot Flashes
J. Clin. Oncol., March 15, 2002; 20(6): 1436 - 1438.
[Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 1993 by Harvey Whitney Books Company.